We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Rtw Biotech Opportunities Ltd | LSE:RTWG | London | Ordinary Share | GG00BKTRRM22 | ORD NPV (GBP) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 116.00 | 112.00 | 120.00 | - | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Trust,ex Ed,religious,charty | 4.17M | -4.76M | -0.0123 | -122.76 | 447.98M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 17/4/2023 14:42 | The announcement that investee company Prometheus Biosciences (Nasdaq RXDX)is to be acquired by Merck for $200/share helps make RTWG an interesting trade over the next few months. At 31 March 2023, RXDX traded around $110 and made up 14.8% of RTWG's NAV. Therefore, this deal adds around 12% to 31 March NAV which was $1.49/about 120p. RTWG has a good long term record and has more often traded at or above NAV, I think. Looks to me like the current offer price of 96.8p is an interesting point to start a new holding. | tiredoldbroker |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
